Owens & Minor $200 million follow-on offering
Davis Polk advised the joint book-running managers and representatives to the underwriters in connection with the approximately $200 million follow-on public offering of…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Beam Therapeutics $127 million offering
Davis Polk advised the joint book-running managers in connection with an SEC-registered offering of 5,750,000 common shares of Beam Therapeutics Inc. for total gross proceeds of $127…
Biondvax Pharmaceuticals $100 million at-the-market offering
Davis Polk advised BiondVax Pharmaceuticals Ltd. in connection with its registered at-the-market offering of shares of its American depositary shares for up to a maximum offering price of …
Gilead Sciences $7.25 billion senior notes offering
Davis Polk advised Gilead Sciences, Inc. in connection with an SEC-registered offering of $7.25 billion aggregate principal amount of senior notes, consisting of (i) $500 million aggregate…
Hologic $950 million senior notes offering
Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S offering by Hologic, Inc. of $950 million aggregate principal amount of its…
Medtronic Global Holdings €6.25 billion notes offering
Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering of €6.25 billion aggregate principal amount of notes by Medtronic Global…
ADC Therapeutics $204 million SEC-registered offering
Davis Polk advised ADC Therapeutics SA on its SEC-registered offering of 6,000,000 common shares for total gross proceeds of $204 million. ADC Therapeutics is listed on the New York…
Zai Lab HK$5.94 billion secondary listing and IPO on the HKEX
Davis Polk advised Zai Lab Limited in connection with its secondary listing and initial public offering on the Hong Kong Stock Exchange. Zai Lab is the first company listed under both…
GoodRx Holdings $1.3 billion IPO
Davis Polk advised the representatives of the several underwriters in connection with the $1.3 billion initial public offering of 39,807,691 shares of Class A common stock of GoodRx…
Omnicell $575 million convertible senior notes offering
Davis Polk advised the representatives of the initial purchasers in a Rule 144A offering by Omnicell, Inc. of $575 million aggregate principal amount of 0.25% convertible senior notes due…